Novavax Inc Stock Price, News & Analysis

Novavax, Inc. (Nasdaq: NVAX) announced participation in the 2nd Annual CybeRx Series: Vaccine Forum on June 22, 2021. The fireside chat will feature discussions around NVX-CoV2373, Novavax's recombinant nanoparticle protein-based COVID-19 vaccine. The event will be moderated by Geoffrey Porges, with Novavax leaders Gregory M. Glenn and John J. Trizzino participating. This forum highlights Novavax's innovative approach to vaccine development, particularly in combating serious infectious diseases.

Novavax, a biotechnology company, announced that Gregory M. Glenn, M.D., its President of Research and Development, will participate in a session at the National Vaccine Advisory Committee meeting on June 17, 2021. The discussion will focus on Novavax' COVID-19 vaccine candidate, NVX-CoV2373. The session is scheduled from 3:15 p.m. to 4:15 p.m. ET, titled Experiences in the Field: COVID-19 Vaccine Authorization and Beyond. Novavax is advancing its vaccine to combat SARS-CoV-2, aiming to enhance global health through innovative vaccines.

Novavax (Nasdaq: NVAX) announced promising results from its first co-administration study of its COVID-19 vaccine candidate, NVX-CoV2373, alongside an influenza vaccine. Conducted in the UK with 431 volunteers, the study showed vaccine efficacy rates of 87.5% for the co-administered group and 89.8% for the main study. The findings suggest that simultaneous vaccination could enhance public health efforts by reducing healthcare visits. The vaccine demonstrated a favorable safety profile, with mild reactogenicity and preserved immunogenicity for the influenza vaccine.

Novavax, Inc. (Nasdaq: NVAX) reported promising results from its PREVENT-19 Phase 3 trial for the COVID-19 vaccine NVX-CoV2373. The vaccine demonstrated 100% efficacy against moderate and severe disease and an overall efficacy of 90.4%, achieving its primary endpoint. The study involved 29,960 participants across the U.S. and Mexico. Novavax plans to apply for regulatory approvals in Q3 2021 and expects to manufacture 100 million doses per month by the end of Q3. The vaccine showed strong efficacy against Variants of Interest and Concern.

Novavax, Inc. (Nasdaq: NVAX) announced promising data on its COVID-19 vaccine candidate, NVX-CoV2373, against the SARS-CoV-2 Beta variant. Recent studies show strong immunogenicity and protection against both Alpha and Beta variants. Results indicated that booster doses of a variant-directed vaccine could enhance immune responses significantly. Notably, mice and baboons demonstrated robust antibody responses, and human trials have shown neutralizing capacity against variants. Further clinical testing is expected to commence in Fall 2021, indicating the potential for broader vaccine protection.

Novavax (NASDAQ: NVAX) will host Maryland Governor Larry Hogan on June 10, 2021, at its future Vaccines Innovation Campus in Gaithersburg. The event at 9:30 AM ET will include a tour and press briefing led by CEO Stanley C. Erck and Greg Glenn, M.D. This follows approval by Gaithersburg's city officials for expansion, enhancing R&D and manufacturing capabilities. Novavax aims to grow its presence in Maryland’s biotech sector while advancing its COVID-19 vaccine and other projects.

Novavax (Nasdaq: NVAX) has announced that CEO Stanley C. Erck will take part in a panel discussion at the BIO International Convention 2021 on June 14. The event, hosted by the Biotechnology Innovation Organization, is scheduled for June 10-11 and June 14-18. The panel will focus on global pandemic preparedness, featuring discussions about Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This protein-based vaccine is designed to combat SARS-CoV-2 and is currently under evaluation in multiple clinical trials.

Novavax (Nasdaq: NVAX), a biotechnology company specializing in vaccines, announced participation in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. The event will feature discussions about its COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John Trizzino. A replay of the session will be available on the company’s website for 90 days. Novavax aims to combat serious infectious diseases through innovative vaccines and is advancing its COVID-19 and NanoFlu vaccine candidates in clinical trials.

Novavax, Inc. (Nasdaq: NVAX) announced that Gregory M. Glenn, M.D., will present on NVX-CoV2373, its COVID-19 vaccine candidate, at the 2021 International Society for Vaccines Virtual Congress on May 25, 2021. The presentation will cover safety, efficacy, and immunogenicity data. A recent analysis from Phase 3 trials in the U.K. shows approximately 90% efficacy against COVID-19, with impressive results against variants. NVX-CoV2373 utilizes Novavax's proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to enhance immune response.